Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance. The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management. Read More
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health breakthroughs, announced that Co-founder and CEO Amro Albanna will present at the NEXT SUPER STOCK livestream hosted by Wall Street Reporter on June 26, 2025, at 1:00 p.m. ET. Albanna will outline Aditxt’s innovation acceleration model, provide updates on its autoimmunity and early cancer detection programs, and share the latest on the company’s pending acquisition of Evofem Biosciences, Inc.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET.
Aditxt (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences (OTCPK: EVFM), to its Board of Directors as the company advances toward commercialization and sharpens its focus on women’s health. Pelletier brings more than 30 years of global pharmaceutical experience, including launching and expanding brands across women’s reproductive health. At Evofem, she led the approval and commercial growth of Phexxi(R) and the acquisition of SOLOSEC(R), marking four straight years of net sales growth. She also holds board roles at Windtree Therapeutics (NASDAQ: WINT) and serves on nonprofit advisory boards focused on women’s empowerment and health.
Aditxt (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences (OTCPK: EVFM), to its Board of Directors as the company advances toward commercialization and sharpens its focus on women’s health. Pelletier brings more than 30 years of global pharmaceutical experience, including launching and expanding brands across women’s reproductive health. At Evofem, she led the approval and commercial growth of Phexxi(R) and the acquisition of SOLOSEC(R), marking four straight years of net sales growth. She also holds board roles at Windtree Therapeutics (NASDAQ: WINT) and serves on nonprofit advisory boards focused on women’s empowerment and health.
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) (“Evofem”), to Aditxt’s Board of Directors.
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt”), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow’s Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences’ CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women’s health, respectively.
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health innovations, announced its decision to terminate the Arrangement Agreement with Appili Therapeutics Inc., effective May 31, 2025. The agreement, first announced in April 2024, had been amended multiple times to address evolving conditions. Aditxt cited a lack of strategic alignment as the reason for discontinuing the deal, despite ongoing respect for Appili’s work. Management plans to formally notify Appili of the termination.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that it has determined it is in the best interest of the Company and its stockholders to terminate the previously announced Arrangement Agreement with Appili Therapeutics, Inc.
Aditxt (NASDAQ: ADTX) announced that Chief Innovation Officer Dr. Shahrokh Shabahang and Adimune Co-CEO Dr. Friedrich Kapp will participate in today’s Aditxt Weekly Update to discuss recent progress on ADI-100, the lead therapeutic candidate of its wholly owned subsidiary, Adimune. The company continues to spotlight advancements within its health innovation portfolio as it accelerates development of novel immune-modulating therapies.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt’s CIO Dr. Shahrokh Shabahang, and Adimune’s Co-CEO Dr. Friedrich Kapp, will join today’s Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune.
Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.
Aditxt, Inc. requests that their press release NewsItemId: 20250417385764 “Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™” be killed.
Aditxt (NASDAQ: ADTX) announced that Dr. Charles Howe of the Mayo Clinic will join the Company’s Weekly Update on May 2, 2025, to discuss key findings from a newly announced preclinical study of ADI-100, the lead therapeutic candidate from Aditxt’s subsidiary, Adimune Inc. The update will also feature Dr. Shahrokh Shabahang, Aditxt’s Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune, highlighting the latest advancements in immune modulation therapy.
Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received Institutional Review Board approval to initiate a clinical study evaluating the Mitomic Endometriosis Test (MET), a blood-based diagnostic aimed at early detection of endometriosis. The study will enroll up to 1,000 participants beginning in May 2025 and compare MET results to laparoscopic diagnoses, the current standard. Designed to detect mitochondrial DNA deletions, MET offers a non-invasive approach that could reduce diagnostic delays impacting millions of women globally. Results may support the test’s launch as a Laboratory Developed Test from Pearsanta’s certified lab.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (MET), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will provide key updates on recent events, including:
Aditxt (NASDAQ: ADTX) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), eliminating the need for a previously scheduled hearing with the exchange’s Hearings Panel. The company’s stock will continue trading on the Nasdaq Capital Market under the ticker ADTX as it advances health innovation efforts targeting autoimmunity, cancer, and other major health challenges.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that it received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The hearing before the Hearings Panel scheduled to take place on April 22, 2025, has been cancelled. The Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol ADTX.
Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health breakthroughs, announced that Don Cilla, Pharm.D., M.B.A., CEO of Appili Therapeutics, will join its Weekly Update on April 4 at 11:30 a.m. ET. The session will spotlight the growing need for infectious disease treatments and explore how partnerships like Aditxt and Appili’s can fast-track health innovations. The discussion will also detail Appili’s $33.2 million in non-dilutive funding, $117 million in new applications, and updates to its U.S. Air Force Academy agreement supporting ATI-1701, a biodefense vaccine candidate.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatments, and the role of partnerships in accelerating promising health innovations.
